Apr 24
David Ewing Duncan at Technology Review worries about the impact of big pharma industry puchases.
The point is that folding the best of biotech into large companies that are having serious trouble developing their own drugs may be a great idea for investors cashing in, but it may end up killing off creativity in drug making.
